Moreover, as IL-6, OSM, and LIF utilize gp130 as a signaling component for high-affinity receptor complexes [28], targeting gp130 to inhibit autocrine LIF and OSM signaling could be another strategy for IDH-mutated AML therapy. The gene discussed is IDH2; the disease is acute myeloid leukemia.